TOKYO, May 14 (Reuters) - Takeda Pharmaceutical Coforecast on Tuesday it would have an operating loss in thecurrent financial year, as it books costs associated with themultibillion-dollar Shire deal.
Japan's biggest drugmaker expects an operating loss of 193billion yen ($1.76 billion) for the year to March 2020, comparedwith a 205 billion yen profit a year earlier.
That compares with an average estimate for the current yearof 227.5 billion yen profit from 12 analysts, compiled byRefinitiv.
Takeda closed a deal to acquire Irish Shire in January.($1 = 109.60 yen)(Reporting by Takashi Umekawa; Editing by Richard Borsuk)
